Delta-Fly Pharma Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Delta-Fly Pharma's earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 11.7% per year.
Key information
-3.4%
Earnings growth rate
7.9%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -11.7% |
| Return on equity | -225.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Delta-Fly Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1,649 | 240 | 1,329 |
| 31 Mar 24 | 0 | -1,429 | 229 | 1,118 |
| 31 Dec 23 | 0 | -1,262 | 237 | 958 |
| 30 Sep 23 | 0 | -1,306 | 245 | 1,009 |
| 30 Jun 23 | 0 | -1,300 | 243 | 1,000 |
| 31 Mar 23 | 0 | -1,328 | 261 | 1,011 |
| 31 Dec 22 | 200 | -1,168 | 270 | 1,051 |
| 30 Sep 22 | 200 | -1,032 | 263 | 921 |
| 30 Jun 22 | 200 | -969 | 262 | 865 |
| 31 Mar 22 | 300 | -967 | 287 | 940 |
| 31 Dec 21 | 300 | -926 | 286 | 895 |
| 30 Sep 21 | 300 | -955 | 289 | 921 |
| 30 Jun 21 | 400 | -915 | 297 | 973 |
| 31 Mar 21 | 300 | -862 | 253 | 866 |
| 31 Dec 20 | 200 | -1,096 | 242 | 1,020 |
| 30 Sep 20 | 200 | -1,288 | 232 | 1,221 |
| 30 Jun 20 | 100 | -1,589 | 222 | 1,430 |
| 31 Mar 20 | 100 | -1,555 | 218 | 1,397 |
| 31 Dec 19 | 0 | -1,402 | 221 | 1,134 |
| 30 Sep 19 | 0 | -1,126 | 216 | 828 |
| 30 Jun 19 | 0 | -787 | 203 | 465 |
| 31 Mar 19 | 0 | -673 | 180 | 376 |
| 31 Mar 18 | 150 | -246 | 194 | 199 |
| 31 Mar 17 | 902 | 305 | 256 | 317 |
Quality Earnings: 4598 is currently unprofitable.
Growing Profit Margin: 4598 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4598 is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare 4598's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4598 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 4598 has a negative Return on Equity (-225.58%), as it is currently unprofitable.